Back to top
more

Senesco Technologies (ELOX)

(Delayed Data from OTC)

$0.75 USD

0.75
1,713

-0.04 (-4.46%)

Updated Apr 26, 2024 12:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ELOX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Senesco Technologies Inc. [ELOX]

Reports for Purchase

Showing records 1 - 20 ( 21 total )

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

10/14/2022

Company Report

Pages: 5

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/09/2022

Company Report

Pages: 8

Bearish Outlook on Upcoming ELX-02 Readout Expected 1H22; PT to $0.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/31/2022

Company Report

Pages: 6

Poor Evidence Plagues ELX-02 Expansion to Alport Syndrome

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/18/2021

Company Report

Pages: 9

Underwhelming ELX-02 Top Line - Our Thoughts; PT Down to $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/11/2021

Company Report

Pages: 8

Negative Outlook For Approaching ELX-02 Readout; PT to $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ELOX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/17/2021

Company Report

Pages: 8

ELX-02 Phase 2 In CF Remains on Track, Pipeline expands to Epidermolysis Bullosa; Reit Neutral and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/10/2021

Company Report

Pages: 8

Platform Future Defined by Zikani Acquisition, Potential For ELX-02

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

04/07/2021

Daily Note

Pages: 5

Pipeline Strategy Rewritten Around Broader Ribosomal RNA Therapeutics-Can the Butterfly Emerge?

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/12/2021

Company Report

Pages: 8

CF Program Data in 1H21, Pre-clinical Assets Continue to Take Shape; Reit Neutral and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/09/2020

Company Report

Pages: 7

Minor Progress Updates as CF Program Readout Slated for 1H21, Reit Neutral and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/10/2020

Company Report

Pages: 7

Continue to Await Data in CF; Reiterate Neutral and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/08/2020

Company Report

Pages: 7

While Awaiting Data in CF a Look at Earlier Stage Assets; Reiterate Neutral and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/06/2020

Company Report

Pages: 6

Awaiting ELX-02 Data in CF Patients Anticipated 1H20,

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/06/2019

Company Report

Pages: 5

Despite CF Program Steps Forward, Phase 2 ELX-02 Data in CF Patients Remains on Horizon.

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/29/2019

Industry Report

Pages: 7

Spotlight on NACFC 2019: Hot Topics and Abstracts of Interest

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/08/2019

Company Report

Pages: 6

ELX-02 Development in CF and Cystinosis, Clinical Data on Horizon; Reit Neutral and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/10/2019

Company Report

Pages: 6

Preclinical Development in Retinal Disorders; We Maintain Our ELX-02 Reservations; Reit Neutral and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

04/01/2019

Daily Note

Pages: 4

Update from the European Cystic Fibrosis Society Basic Science Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Senesco Technologies Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/11/2019

Company Report

Pages: 5

Awaiting More Convincing Data From ELX-02

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party